Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 118

Similar articles for PubMed (Select 23738794)

1.

Novel approaches to glioma drug design and drug screening.

Patil SA, Hosni-Ahmed A, Jones TS, Patil R, Pfeffer LM, Miller DD.

Expert Opin Drug Discov. 2013 Sep;8(9):1135-51. doi: 10.1517/17460441.2013.807248. Epub 2013 Jun 6. Review.

PMID:
23738794
2.

Chemotherapy for malignant gliomas.

Kreisl TN.

Semin Radiat Oncol. 2009 Jul;19(3):150-4. doi: 10.1016/j.semradonc.2009.02.003.

PMID:
19464629
3.

Molecularly targeted therapies for malignant gliomas: advances and challenges.

Penas-Prado M, Gilbert MR.

Expert Rev Anticancer Ther. 2007 May;7(5):641-61. Review.

PMID:
17492929
4.

Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.

Lefranc F, Rynkowski M, DeWitte O, Kiss R.

Adv Tech Stand Neurosurg. 2009;34:3-35. Review.

PMID:
19368079
5.

Cell surface receptors in malignant glioma.

Li YM, Hall WA.

Neurosurgery. 2011 Oct;69(4):980-94; discussion 994. doi: 10.1227/NEU.0b013e318220a672. Review.

PMID:
21522029
6.

Drug delivery strategies for the treatment of malignant gliomas.

Allhenn D, Boushehri MA, Lamprecht A.

Int J Pharm. 2012 Oct 15;436(1-2):299-310. doi: 10.1016/j.ijpharm.2012.06.025. Epub 2012 Jun 19. Review.

PMID:
22721856
7.

Local treatment of malignant brain tumors using implantable chemotherapeutic polymers.

Gallia GL, Brem S, Brem H.

J Natl Compr Canc Netw. 2005 Sep;3(5):721-8. Review.

PMID:
16194460
8.

Therapeutic targeting of EGFR in malignant gliomas.

Ye F, Gao Q, Cai MJ.

Expert Opin Ther Targets. 2010 Mar;14(3):303-16. doi: 10.1517/14728221003598948. Review.

PMID:
20148717
9.

Standard of care and future pharmacological treatment options for malignant glioma: an urgent need for screening and identification of novel tumor-specific antigens.

Batich KA, Sampson JH.

Expert Opin Pharmacother. 2014 Oct;15(14):2047-61. doi: 10.1517/14656566.2014.947266. Epub 2014 Aug 19. Review.

PMID:
25139628
10.

Chemotherapy for gliomas.

Chang SM, Prados MD.

Curr Opin Oncol. 1995 May;7(3):207-13. Review.

PMID:
7654821
11.

Chemotherapy and novel therapeutic approaches in malignant glioma.

Desjardins A, Rich JN, Quinn JA, Vredenburgh J, Gururangan S, Sathornsumetee S, Reardon DA, Friedman AH, Bigner DD, Friedman HS.

Front Biosci. 2005 Sep 1;10:2645-68. Review.

PMID:
15970525
12.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
13.

The blood-brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery.

Zhan C, Lu W.

Curr Pharm Biotechnol. 2012 Sep;13(12):2380-7. Review.

PMID:
23016643
14.

Preliminary individual adjuvant therapy for gliomas based on the results of molecular biological analyses for drug-resistance genes.

Tanaka S, Kamitani H, Amin MR, Watanabe T, Oka H, Fujii K, Nagashima T, Hori T.

J Neurooncol. 2000;46(2):157-71.

PMID:
10894369
15.

Non-cytotoxic drugs as potential treatments for gliomas.

Drappatz J, Wen PY.

Curr Opin Neurol. 2004 Dec;17(6):663-73. Review.

PMID:
15542974
16.

New treatment strategies for malignant gliomas.

Sathornsumetee S, Rich JN.

Expert Rev Anticancer Ther. 2006 Jul;6(7):1087-104. Review.

PMID:
16831080
17.

Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo.

Rieger L, Rieger J, Winter S, Streffer J, Esser P, Dichgans J, Meyermann R, Weller M.

Acta Neuropathol. 2000 May;99(5):555-62.

PMID:
10805101
18.

Targeting core (mutated) pathways of high-grade gliomas: challenges of intrinsic resistance and drug efflux.

Lin F, de Gooijer MC, Hanekamp D, Brandsma D, Beijnen JH, van Tellingen O.

CNS Oncol. 2013 May;2(3):271-88. doi: 10.2217/cns.13.15. Review.

PMID:
25054467
19.

Convection-enhanced delivery: targeted toxin treatment of malignant glioma.

Hall WA, Sherr GT.

Neurosurg Focus. 2006 Apr 15;20(4):E10. Review.

PMID:
16709015
20.

Molecularly targeted therapies for malignant gliomas.

Argyriou AA, Kalofonos HP.

Mol Med. 2009 Mar-Apr;15(3-4):115-22. doi: 10.2119/molmed.2008.00123. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk